D
DiogenX
Biotech & Life Sciences · Marseille, France · Founded 2019
Beta-Cell recovery to counter diabetes MoreLess
Developer of therapeutic services intended to serve diabetic patients. The company provides pancreatic beta-cell modulators for the treatment of type 1 and type 2 diabetes by developing a candidate molecule that regenerates pancreatic insulin-producing cells in patients with diabetes, enabling patients to get benefits in terms of quality of life and survival. Keywords: Pharmaceuticals and Biotechnology, Autoimmune Disorder, Beta-Cell Recovery, Cell System, Diabetic Patient, Pancreatic Beta-Cells, Peripheral Target.
Company overview
DiogenX company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2019
- Headquarters
- Marseille, France
- Employees
- 24
- Open positions
- None listed
- Dealroom signal
- 88.0
Valuation & funding
DiogenX funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Nov 2023 | $6.6M | $151M | Sunstone Life Science Ventures | ↗ |
| SERIES A✓Equity / VC | May 2023 | $30M | $121M | Boehringer Ingelheim Venture Fund · Omnes Capital · Roche Venture Fund · JDRF T1D Fund | ↗ |
| GRANT✓Other financing | Mar 2023 | $2.5M | — | European Innovation Council | — |
| SEED✓Equity / VC | Jun 2020 | $5M | $20M | Boehringer Ingelheim Venture Fund · JDRF T1D Fund · AdBio partners | — |
| SPINOUT✓Other financing | Jan 2019 | — | — | INSERM · CNRS Innovation · Aix-Marseille University · French National Centre for Scientific Research - CNRS | ↗ |
Financials
Revenue and workforce over time
Available revenue and workforce history. Fields without reported data are omitted.
| Year | Revenue | Growth | Employees |
|---|---|---|---|
| 2026 | $11K | 0% | 25 |
| 2025 | $11K | 0% | 22 |
| 2024 | $11K | 0% | 18 |
| 2023 | $11K | 0% | 11 |
| 2022 | $11K | 0% | 11 |
| 2021 | $11K | 0% | — |
| 2020 | $11K | — | — |
Growth signals
DiogenX website traffic
Latest recorded traffic for DiogenX is 1.2K monthly website visits, up 192.7% over the last three months. DiogenX's team grew 9.1% over the past year.
Comparisons
DiogenX compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
DiogenX's talent
Source: Dealroom Talent Intelligence.
Investors
13 investors on DiogenX's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where DiogenX has talent and traffic
team presence
In the news
Latest news about DiogenX
Recent press, funding announcements, and product moves mentioning DiogenX — open to read from the original sources.
Market sentiment
What the market is saying about DiogenX
An AI-synthesized read of the highest-engagement posts about DiogenX on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See DiogenX’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.